Kamada Ltd. (KMDA) News
Filter KMDA News Items
KMDA News Results
|Loading, please wait...|
Latest KMDA News From Around the Web
Below are the latest news stories about Kamada Ltd that investors may wish to consider to help them evaluate KMDA as an investment opportunity.
Wall Street brokerages forecast that Kamada Ltd. (NASDAQ:KMDA) will report sales of $23.37 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Kamada’s earnings. The lowest sales estimate is $22.24 million and the highest is $24.50 million. Kamada reported sales of $31.54 million during the same quarter last […]
Equities analysts expect that Kamada Ltd. (NASDAQ:KMDA) will announce $0.02 earnings per share for the current quarter, according to Zacks. Two analysts have issued estimates for Kamadas earnings. The highest EPS estimate is $0.04 and the lowest is ($0.01). Kamada reported earnings of $0.04 per share in the same quarter last year, which suggests a 
Wall Street analysts predict that Kamada Ltd. (NASDAQ:KMDA) will post $23.37 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Kamadas earnings, with estimates ranging from $22.24 million to $24.50 million. Kamada posted sales of $31.54 million during the same quarter last year, which would indicate 
Kamada Ltd. (NASDAQ:KMDA) saw a significant drop in short interest in the month of November. As of November 15th, there was short interest totalling 546,800 shares, a drop of 21.3% from the October 31st total of 695,200 shares. Based on an average daily volume of 49,200 shares, the days-to-cover ratio is presently 11.1 days. Currently, 
Zacks Investment Research downgraded shares of Kamada (NASDAQ:KMDA) from a hold rating to a sell rating in a research note released on Wednesday, Zacks.com reports. According to Zacks, Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and 
HC Wainwright restated their buy rating on shares of Kamada (NASDAQ:KMDA) in a research note issued to investors on Tuesday, Zacks.com reports. Other analysts have also recently issued reports about the company. Zacks Investment Research upgraded Kamada from a sell rating to a hold rating in a research report on Wednesday, October 13th. TheStreet cut  The post Kamada (NASDAQ:KMDA) Receives Buy Rating from HC Wainwright appeared first on ETF Daily News .
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Kamada (KMDA) and Verastem (VSTM)
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Universal Health (UHS – Research Report), Kamada (KMDA – Research Report) and Verastem (VSTM – Research Report) with bullish sentiments. Universal Health (UHS) In a report released yesterday, Ann Hynes from Mizuho Securities reiterated a Buy rating on Universal Health, with a price target of $151.00. The company's shares closed last Monday at $127.23, close to its 52-week low of $121.23. According to TipRanks.
Kamada (NASDAQ:KMDA) issued its earnings results on Sunday. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05), MarketWatch Earnings reports. Kamada had a return on equity of 6.73% and a net margin of 10.42%. During the same period last year, the firm posted $0.15 […]
Kamada (NASDAQ:KMDA) released its quarterly earnings data on Sunday. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05), MarketWatch Earnings reports. Kamada had a net margin of 10.42% and a return on equity of 6.73%. During the same period in the prior year, the […]
Kamada Ltd (NASDAQ: KMDA ) has acquired four FDA-approved plasma-derived hyperimmune commercial products from Saol Therapeutics . Kamada will pay Saol a $95 million upfront payment and an additional $50 million in sales milestones during 2022-2034. The combined annual global revenue of the acquired portfolio in 2021 is expected to be $40 million - $45 Full story available on Benzinga.com